Outcomes, Pulmonary and Transplant - Cardiovascular Update

Continuous heart monitoring to evaluate treatment effects in pulmonary hypertension

Open Heart

MAY 7, 2024

Background The treatment of pulmonary hypertension (PH) has improved rapidly in recent decades. There is increasing evidence to support the role of early intervention and treatment in affecting clinical outcomes in PH. Methods Patients were compared before and after treatment escalation.

Heart Monitor

Heart Monitor Pulmonary Hypertension Angioplasty

The comparative impact of central vs. peripheral VA-ECMO cannulation on postoperative graft dysfunction in lung transplantation: a retrospective analysis

Frontiers in Cardiovascular Medicine

FEBRUARY 24, 2025

BackgroundLung transplantation (LTx) is the definitive treatment for end-stage pulmonary diseases, with venoarterial extracorporeal membrane oxygenation (VA-ECMO) used as a common perioperative support. Data included recipient/donor demographics, preoperative status, and follow-up outcomes.

Transplant

Transplant ICU Pulmonary Hospital

Transcatheter Palliation With Pulmonary Artery Flow Restrictors in Neonates With Congenital Heart Disease: Feasibility, Outcomes, and Comparison With a Historical Hybrid Stage 1 Cohort

Circulation: Cardiovascular Interventions

NOVEMBER 6, 2023

Background:Neonates with complex congenital heart disease and pulmonary overcirculation have been historically treated surgically. Pulmonary arteries grew adequately for age, and devices were easily removed without complications. Circulation: Cardiovascular Interventions, Ahead of Print. kilograms [IQR, 2.1–3.3]) months (IQR, 4.0–10.8),

Congenital Heart Disease

Congenital Heart Disease Congenital Heart Disease Pulmonary

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Uric acid in advanced heart failure: relation to central haemodynamics and outcome

Open Heart

NOVEMBER 25, 2022

Cox models were created to investigate if UA was a significant predictor of adverse outcome where log1.1(UA) UA) was used to estimate the effect on outcome associated with a 10% increase in UA levels. Median UA was 0.48 (0.39–0.61) mmol/L.

Heart Failure

Heart Failure Outcomes Heart Transplant Artificial Heart

Trends in Ductus Arteriosus Stent Versus Blalock?Taussig?Thomas Shunt Use and Comparison of Cost, Length of Stay, and Short?Term Outcomes in Neonates With Ductal?Dependent Pulmonary Blood Flow: An Observational Study Using the Pediatric Health Information Systems Database

Journal of the American Heart Association

DECEMBER 1, 2023

BackgroundThe modified Blalock‐Taussig‐Thomas shunt is the gold standard palliation for securing pulmonary blood flow in infants with ductal‐dependent pulmonary blood flow. Intervention was not significantly associated with odds of 30‐day transplant‐free survival (OR,1.18 [95% CI, 0.70–1.99])

Pediatrics

Pediatrics Stents Stent Pulmonary

Prognostic value of three iron deficiency definitions in patients with advanced heart failure

European Journal of Heart Failure

DECEMBER 13, 2023

Venn diagram of iron deficiency (ID) according to various definitions and associated outcomes. We evaluated three definitions of ID in patients referred for heart transplantation. Methods and results Consecutive patients assessed for heart transplantation at a single UK centre between January 2010 and May 2022 were included.

Heart Failure

Heart Failure Heart Transplant Transplant Pulmonary

Effects of atrial fibrillation ablation on arrhythmia burden and ventricular function in end‐stage heart failure: Lessons from CASTLE‐HTx

European Journal of Heart Failure

FEBRUARY 25, 2025

PVI, pulmonary vein isolation. Abstract Aims The CASTLE-HTx trial showed the benefit of atrial fibrillation (AF) ablation compared to medical therapy in decreasing mortality, need for left ventricular assist device implantation or heart transplantation (HTx) in patients with end-stage heart failure (HF).

Atrial Fibrillation

Atrial Fibrillation Ablation Heart Failure Arrhythmia

ZENITH: Sotatercept Effectively Reduces Composite Outcome in High-Risk PAH

American College of Cardiology

MARCH 31, 2025

25 in Chicago and simultaneously published in NEJM.

Transplant

Transplant Outcomes Pulmonary Hypertension

Prognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension

Open Heart

JUNE 8, 2022

Objective Pulmonary arterial hypertension (PAH), caused by pulmonary artery remodelling and increased pulmonary vascular resistance (PVR) due to an unknown mechanism, is an intractable disease with a poor prognosis. The primary outcome was death or lung transplantation.

Pulmonary

Pulmonary Hypertension Transplant Risk Factors

Endotronix Receives FDA Premarket Approval of the Cordella PA Sensor System for the Treatment of Heart Failure

DAIC

JUNE 24, 2024

Food and Drug Administration ( FDA ) of the company's Cordella Pulmonary Artery (PA) Sensor System for the treatment of New York Heart Failure (NYHA) class III heart failure patients. PROACTIVE-HF demonstrated that with Cordella clinicians achieved more optimal and timely dosing of key HF medications, significantly improving outcomes.

Heart Failure

Heart Failure Reimbursement Heart Transplant Pulmonary

Use of Right Ventricular Free-Wall Strain in a Multivariable Estimate of Right Ventricular-Arterial Coupling in Pediatric Pulmonary Arterial Hypertension

Circulation: Cardiovascular Imaging

DECEMBER 16, 2024

BACKGROUND:Right ventricular-arterial coupling (RVAC) describes the relationship between right ventricular contractility and pulmonary vascular afterload. In a retrospective analysis, hybrid (echo and invasive) RVAC metrics included TAPSE/pulmonary vascular resistance (PVRi) and RVFW-LS/PVRi.

Pediatrics

Pediatrics Pulmonary Congenital Heart Disease Hypertension

Advanced hemodynamics for prognostication in heart failure: the pursuit of the patient-specific tipping point

Frontiers in Cardiovascular Medicine

MARCH 3, 2024

Background Objective tools to define the optimal time for referral for advanced therapies and to help guide escalation and de-escalation of support can improve management decisions and outcomes for patients with advanced heart failure. Results Approximately 1010 discrete heart failure scenarios were modeled.

Heart Failure

Heart Failure Cardiogenic Shock Physiology Transplant

Abstract Sa1109: Aerobic Capacity of Adults with Fontan Palliation: Disease-specific Reference Values and Relationship to Outcomes

Circulation

NOVEMBER 11, 2024

Background:Patients with Fontan palliation have reduced aerobic capacity because of impaired cardiac, pulmonary, and skeletal muscle function. We assessed the correlates of predicted peak VO2, and the relationship between predicted peak VO2quartiles and cardiovascular outcomes (death/transplant).Results:Of 15.2 - 23.9)

Transplant

Transplant Outcomes Exercise Cardiovascular Disease

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

MARCH 13, 2024

To my knowledge, no therapy has been proven to reduce mortality in these patients, and CardiAMP Heart Failure II has great potential to achieve this outcome by confirming our CardiAMP Heart Failure Trial results.” Getty Images milla1cf Wed, 03/13/2024 - 16:49 March 13, 2024 — BioCardia, Inc. , said Peter Altman , PhD.,

CMS

CMS Heart Failure Reimbursement Quality of Life

Heart failure patients with improved ejection fraction: Insights from the MECKI score database

European Journal of Heart Failure

OCTOBER 3, 2023

Characteristics of heart failure with improved ejection fraction (HFimpEF) patients and outcome comparison with heart failure with persistently reduced ejection fraction (pHFrEF). CV mortality is the composite endpoint for CV mortality + urgent transplant + left ventricular assist device implantation. Events per 1000 person-years. #

Heart Failure

Heart Failure Exercise Laboratory Transplant

A teenager with chest pain, a troponin below the limit of detection, and "benign early repolarization"

Dr. Smith's ECG Blog

JANUARY 9, 2023

CT angiogram chest: no aortic dissection or pulmonary embolism. Serial chest xrays: progressive bilateral pulmonary edema. The last information available is that the patient was undergoing heart transplant evaluation. She died before she could get a heart transplant. No further troponins were measured.

Chest Pain

Chest Pain Aneurysm STEMI Thrombosis

Published Research

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Published Research kschukar Thu, 04/20/2023 - 11:12 Recently published (2016 – present) manuscripts utilizing STS data: Adult Cardiac Surgery, General Thoracic Surgery, Congenital Heart Surgery, and Intermacs/Pedimacs.

Research

Research Coronary Artery Bypass Graft Aortic valve Congenital

Published Research

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)

Research

Research Coronary Artery Bypass Graft Aortic valve Congenital

Continuous heart monitoring to evaluate treatment effects in pulmonary hypertension

The comparative impact of central vs. peripheral VA-ECMO cannulation on postoperative graft dysfunction in lung transplantation: a retrospective analysis

Transcatheter Palliation With Pulmonary Artery Flow Restrictors in Neonates With Congenital Heart Disease: Feasibility, Outcomes, and Comparison With a Historical Hybrid Stage 1 Cohort

Webinars

Uric acid in advanced heart failure: relation to central haemodynamics and outcome

Trends in Ductus Arteriosus Stent Versus Blalock?Taussig?Thomas Shunt Use and Comparison of Cost, Length of Stay, and Short?Term Outcomes in Neonates With Ductal?Dependent Pulmonary Blood Flow: An Observational Study Using the Pediatric Health Information Systems Database

Prognostic value of three iron deficiency definitions in patients with advanced heart failure

Effects of atrial fibrillation ablation on arrhythmia burden and ventricular function in end‐stage heart failure: Lessons from CASTLE‐HTx

ZENITH: Sotatercept Effectively Reduces Composite Outcome in High-Risk PAH

Prognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension

Endotronix Receives FDA Premarket Approval of the Cordella PA Sensor System for the Treatment of Heart Failure

Use of Right Ventricular Free-Wall Strain in a Multivariable Estimate of Right Ventricular-Arterial Coupling in Pediatric Pulmonary Arterial Hypertension

Advanced hemodynamics for prognostication in heart failure: the pursuit of the patient-specific tipping point

Abstract Sa1109: Aerobic Capacity of Adults with Fontan Palliation: Disease-specific Reference Values and Relationship to Outcomes

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Heart failure patients with improved ejection fraction: Insights from the MECKI score database

A teenager with chest pain, a troponin below the limit of detection, and "benign early repolarization"

Published Research

Published Research

Stay Connected